Erythropoietin Stimulating Agent Market Size is Expected to Reach $7.6 billion By 2030: IndustryARC

The Global Erythropoietin Stimulating Agent Market size is predicted to reach $7.6 billion by 2030, growing at a CAGR of 3.5% over the forecast period 2023-2030 according to the latest market research report published by IndustryARC. The growing incidences of chronic kidney disease and cancer, rising applications in cancer and cancerization of erythropoietin biosimilars are poised to propel the market growth, finds IndustryARC in its recent report, titled “Erythropoietin Stimulating Agent Market Size, Share & Trends Analysis Report By Product Type (Epoetin-Alfa, Epoetin-Beta, Epoetin-Zeta, Epoetin-Omega, Darbepoetin-Alfa, Others), By Disease Cured (Oncology Diseases [Breast Cancer, Lung Cancer, Liver Cancer, Head & Neck Cancer, Blood Cancer, Others], Kidney Disorders, Neural Disease, Wound Healing, Others), By Application (Hospitals, Clinics, Others), By Region and Segment Forecasts, 2023-2030”

 

 

The Erythropoietin Stimulating Agent industry in the Asia Pacific region is expanding due to healthcare infrastructures and a rising prevalence of chronic conditions, this region is experiencing the fastest market expansion globally. Government support, increased healthcare spending, and a growing focus on innovative treatments drive the heightened demand for ESAs. With a burgeoning patient base and a proactive approach to healthcare advancements, the Asia-Pacific market demonstrates substantial potential for sustained growth and significant market penetration in the ESA segment.

The Epoetin-Alfa segment had the largest market share of 37% in 2022. Its widespread usage is attributed to established efficacy, well-documented safety profiles, and extensive clinical experience. As a synthetic form of erythropoietin, Epoetin-Alfa effectively addresses anemia associated with chronic kidney disease, cancer treatments and other conditions. Its versatility, coupled with a robust market presence, solidifies its position as a preferred choice for healthcare providers. With a proven track record and continual trust among practitioners, Epoetin-Alfa remains at the forefront, shaping the landscape of the ESA market and meeting the diverse needs of patients across various therapeutic areas. 

Oncology Diseases is analyzed to grow with the highest CAGR of 4.1% during the forecast period 2023-2030. With an increasing prevalence of cancer-related anemia, the demand for ESA therapies in oncology is escalating. These agents play a pivotal role in managing anemia associated with cancer treatments, addressing the critical need for erythropoiesis stimulation in patients undergoing chemotherapy or radiation therapy. As oncology treatments advance and the focus on improving patient outcomes intensifies, the ESA market experiences significant growth in the oncology segment. This surge reflects the vital role ESA treatments play in enhancing the quality of life for cancer patients undergoing rigorous therapeutic regimens. In 2023, According to American Cancer Society Association Report, the United States has witness 1,958,310 new cancer cases, resulting in 609,820 cancer-related deaths. Notably, incidence trends demonstrate a more favorable outlook for men compared to women. These statistics carry implications for the Erythropoietin Stimulating Agent (ESA) market. The rising number of cancer cases underscores the potential demand for ESA treatments to manage cancer-related anemia, presenting an opportunity for the ESA market to address the specific needs arising from increased cancer incidence.

Europe region held a major market share of 37% in 2022 owing to its robust healthcare infrastructure, extensive research initiatives and high prevalence of chronic diseases requiring ESA treatments. With well-established regulatory frameworks ensuring safe and effective medication use, Europe showcases a strong market penetration for ESA therapies. The region's emphasis on healthcare innovation, coupled with a proactive approach to addressing anemia-related conditions, positions Europe at the helm of ESA adoption and market expansion, setting benchmarks for quality care and treatment accessibility within the industry. In 2022, According to Cancer Research UK, smoking is the largest cause of cancer in the UK, accounting for 15% of all cancer cases which has resulted in an increase in ESA consumption and has in turn resulted in the growth of this market.

Tailoring ESA therapies to individual patient needs, including personalized dosing strategies, innovative delivery methods, and enhanced patient education, addresses the unique requirements of diverse healthcare scenarios. This approach not only enhances treatment efficacy but also fosters greater patient compliance and satisfaction. The industry's shift towards patient-centric solutions aligns with the evolving paradigm of personalized medicine, offering a more precise and targeted approach to ESA treatment. Manufacturers and healthcare providers focusing on these patient-centric innovations are well-positioned to capitalize on this opportunity, meeting the increasing demand for tailored and effective erythropoiesis-stimulating therapies.

The prevalence of chronic kidney disease is rising quickly, especially in emerging nations, making it a serious public health issue on a global scale. One of the most popular forms of treatment for those with chronic kidney disease is dialysis, and as chronic kidney disease becomes more and more widespread, thus, increases the demand for dialysis.  With the rising demand for dialysis services, developing nations are making investments in the infrastructure of the healthcare system, including the construction of new dialysis facilities. As these medications are used to treat anemia, a common complication of chronic kidney disease, in those with the disease, this presents a market opportunity for stimulating agents.

In 2022, as per the NCBI report. It revealed a contrast in chronic kidney disease (CKD) age-standardized prevalence across different regions. In high-income countries, CKD prevalence stood at 8.6% in men and 9.6% in women. Conversely, in low- and middle-income countries, the prevalence was notably higher at 10.6% in men and 12.5% in women.  Variances in CKD prevalence emphasize potential divergences in ESA demand and usage patterns across regions.

The burgeoning applications of Erythropoietin Stimulating Agents (ESAs) in conditions like HIV infections and end-stage renal disorders represent a significant growth opportunity for the market. With a rising incidence of anemia associated with HIV and an increasing prevalence of end-stage renal disorders globally, the demand for effective ESA treatments is expanding. ESAs play a pivotal role in managing anemia in these populations, addressing erythropoietin deficiency and improving patients' quality of life. The market's growth trajectory is propelled by the growing recognition of ESAs as essential therapeutic options in these specialized segments. As healthcare providers focus more on comprehensive care for patients with complex conditions, the application of ESAs in HIV infections and end-stage renal disorders is poised to significantly contribute to market expansion and therapeutic advancements.

  

Anemia, prevalent across diverse medical conditions such as chronic kidney disease, cancer, and certain chronic illnesses, underscores the critical need for effective treatments like ESAs. As the global population ages and chronic diseases become more prevalent, the incidence of anemia rises, creating a growing demand for therapies that stimulate red blood cell production. ESAs play a pivotal role in managing anemia, addressing the root cause, and enhancing patients' quality of life. This expanding disease burden accentuates the crucial role of ESAs in combating anemia-associated complications, positioning the market for substantial growth opportunities as healthcare providers seek efficient and reliable treatments to address the increasing prevalence of anemia across various patient populations.

In 2023, As per World Health Organization (WHO) report, the global estimates on anemia prevalence are approximately 40% of children aged 6–59 months, 37% of pregnant women, and 30% of women aged 15–49 years are affected by anemia. The widespread prevalence of anemia across diverse age groups and demographics signifies a substantial potential demand for ESA treatments to address anemia-related conditions

 

• Erythropoietin Stimulating Agent Market Size and Forecast 

• Erythropoietin Stimulating Agent Market Trends

• Erythropoietin Stimulating Agent Market Analysis by Product Type

 

• CAGR of the market over the forecast period 2023-2030

• Value Chain analysis of key stake holders

• Detailed analysis of market drivers and opportunities during the forecast period

• Erythropoietin Stimulating Agent Market size estimation and forecast

• Analysis and predictions on end users’ behavior and upcoming trends 

• Competitive landscape and Vendor market analysis including offerings, developments, and financials

• Comprehensive analysis of challenges and constraints in the Erythropoietin Stimulating Agent Market

 

• The COVID-19 pandemic significantly influenced the Erythropoietin Stimulating Agent (ESA) market, triggering substantial shifts in demand dynamics and operational landscapes. Supply chain disruptions, lockdown measures, and healthcare system strains disrupted ESA manufacturing, distribution, and patient access. Treatment delays and altered healthcare-seeking behaviours impacted ESA usage patterns. Additionally, regulatory challenges and market uncertainties intensified the market's volatility. However, amidst these challenges, the pandemic highlighted the importance of innovative healthcare solutions, potentially fostering a climate for ESA market recovery and adaptation. Strategic responses, including agile supply chain management and adapting to evolving healthcare needs will be pivotal for stakeholders navigating the pandemic's enduring impact on the ESA market.

• The Ukraine crisis has injected notable uncertainties into the Erythropoietin Stimulating Agent (ESA) market. Geopolitical tensions and disruptions in the region have reverberated through the global supply chain, affecting ESA manufacturing and distribution. Fluctuations in raw material availability and increased logistical challenges pose risks to market stability. Regulatory complexities further contribute to the impact, requiring market stakeholders to navigate evolving compliance landscapes. While challenges persist, strategic adaptations such as diversifying supply sources and robust risk management, become imperative. The crisis underscores the importance of resilience and proactive strategies for ESA market players in mitigating the multifaceted effects of the Ukraine crisis.

 

 

The Global Erythropoietin Stimulating Agent Market is fragmented with several global and regional companies operating with expansive manufacturing capabilities and extensive distribution networks. The key companies profiled are listed below:

• Amgen Inc.

• Amgen Inc.

• Johnson & Johnson 

• F. Hoffmann La Roche Ltd.

• Novartis (Sandoz)

• Pfizer Inc.

• Kyowa Hakko

• 3S BIO Group

• Teva Pharmaceutical Industries Ltd.

• Kissei Group

• Sanwa Kagaku Kenkyusho

Erythropoietin Drugs Market – The Erythropoietin Drugs Market is projected to grow at a CAGR of 9.7% from 2024 to 2030. Erythropoietin drugs (EPO) are used to treat people undergoing chemotherapy or treatments related to HIV. Globally, demand for Erythropoietin drugs (EPO) is driven by an increasing population with HIV, Cancer and Renal diseases.

Asthma & COPD Drugs Market – The Asthma & COPD Drugs Market is projected to grow at a CAGR of 4.7% from 2024 to 2030. The Growth is attributed to the increasing predominance of asthma and chronic obstructive pulmonary disorder (COPD) requiring the application of anticholinergics and surging technological progress across the world.

Advanced Parenteral Drug Delivery Devices Market – The Advanced Parenteral Drug Delivery Devices Market is projected to grow at a CAGR of 18.4% from 2024 to 2030. The prevalence of chronic diseases and the increasing use of vaccinations and Novel trends in parenteral drug delivery devices are boosting the product demand are driving the Advanced Parenteral Drug Delivery Devices market growth. 

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  

 

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.

Mr. Venkat Reddy

IndustryARC

Email: [email protected]

USA: (+1) 518-282-4727

Web: https://www.industryarc.com

Follow us on: LinkedIn | Facebook | Twitter